Leica Microsystems and Epitomics Enter Agreement for Supply of Proprietary Rabbit Monoclonal Antibodies
Newcastle-upon-Tyne, England - February 29, 2012
Leica Microsystems and Epitomics, Inc. announced today that they had reached an agreement for the supply of proprietary rabbit monoclonal antibodies to Leica Microsystems, based on Epitomics, RabMAb® technology. The agreement also provides long-term support for Leica’s incorporation of Epitomics’ products into higher regulatory classifications of IVD products.
“We are very pleased to enter into this strategic relationship with Epitomics” comments Dr. Konstantin Fiedler, Vice President of Advanced Staining for Leica’s Biosystems Division. “In December we released the first one-step double staining detection system, Leica ChromoPlex 1™ Dual Detection for BOND. Our agreement with Epitomics will allow us to build a supporting range of antibody cocktails based of the leading Novocastra™ mouse monoclonal antibodies and Epitomics RabMAb® rabbit monoclonal antibodies. Additionally, with a selection of Epitomics’ rabbit monoclonal antibodies we will also be able to further strengthen our portfolio of Novocastra concentrated and Bond Ready-to-Use antibody selection for our BOND instruments.”
“We are very pleased to see our RabMabs are incorporated into one of the most advanced automated immunohistochemistry (IHC) staining systems for pathology laboratories in the world. This agreement is another important endorsement of the quality of Epitomics products in the rapidly growing field of IHC for anatomic pathology. Epitomics has accumulated a collection of candidate antibodies for potential future incorporation into companion diagnostics products in recent years. This strategic relationship will take us to the next level.” says Dr. Guo-Liang Yu, President and CEO of Epitomics Inc.